Your session is about to expire
← Back to Search
Pembrolizumab for Mesothelioma
Study Summary
This trial is testing how well pembrolizumab works in treating patients with malignant mesothelioma. Pembrolizumab is a monoclonal antibody that works by blocking PD-1, which may stimulate an immune response and kill tumor cells.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My blood clotting time is normal or managed with medication.I have been diagnosed with HIV.My cancer is a confirmed type of mesothelioma.I have a lung condition not caused by an infection.My side effects from previous treatments are mild or back to normal.I haven't had a monoclonal antibody treatment in the last 4 weeks or have recovered from its side effects.You have a specific amount of disease that can be measured using specific criteria for peritoneal or pleural mesothelioma.I am fully active or restricted in physically strenuous activity but can do light work.I have mild to moderate nerve damage.You have active hepatitis B or C.My cancer got worse after treatment with pemetrexed and platinum-based chemotherapy.You have a platelet count of at least 100,000 per microliter.Your hemoglobin level is 9 grams per deciliter or higher.I have an immune system disorder or have been on steroids or other immune-weakening medicines in the last week.I haven't had cancer treatment in the last 2 weeks or I've recovered from its side effects.I have recovered from any major surgery before starting treatment.I have another cancer, but it's either being treated, not growing, or won't affect my life expectancy.I have stable brain metastases, no new brain tumors, and haven't used steroids in the last 7 days.I don't have an active autoimmune disease needing treatment in the last 3 months, except for stable hypothyroidism or Sjogren's syndrome.I am using two birth control methods or am not having sex to join this study.I agree to use birth control during and for 4 months after the study treatment.My blood clotting time is normal or managed if I'm on blood thinners.I have been treated with specific immune system targeting drugs before.I've had 2 or fewer previous chemotherapy treatments, including pemetrexed and platinum.I have not had treatment and either refuse or can't tolerate standard chemotherapy, approved by the study lead.My liver function tests are within the required limits.My kidney function is within the required range.You have a sufficient number of a type of white blood cell called neutrophils.I have not received a live vaccine in the last 30 days.My cancer's PD-L1 status matches the criteria set in Part A of the trial.Your bilirubin levels in the blood are within a certain range.I am currently being treated for an infection.I have provided a tissue sample from my tumor for analysis.
- Group 1: Treatment (pembrolizumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is Pembrolizumab a novel or established therapeutic agent in clinical trials?
"To date, 961 active clinical trials are examining the efficacy of Pembrolizumab; 122 of which have entered Phase 3. This study is being conducted in many parts of the world, with 35727 sites based primarily in Houston, Texas."
How many individuals have been approved to participate in this research project?
"As of this moment, recruitment for the aforementioned clinical trial has been suspended. Originally posted on March 31st 2015 and last edited April 18th 2022, those wishing to be involved in a similar study can find 2,606 trials actively looking participants with peritoneal malignant mesothelioma and 961 research projects involving Pembrolizumab."
Are the doors open to new participants for this research project?
"According to clinicaltrials.gov, this medical trial is no longer enrolling patients; the initial post was on March 31st 2015 and the last update occurred on April 18th 2022. Fortunately, there are currently 3567 other studies that are actively recruiting participants."
What medical concerns is Pembrolizumab typically used to address?
"Pembrolizumab is utilized in the management of several malignant neoplasms, including unresectable melanoma, microsatellite instability high, and progressive disease post-chemotherapy."
To what extent can Pembrolizumab pose a risk to individuals?
"Although there is some evidence that Pembrolizumab is safe, the lack of efficacy data meant it received a ranking of 2 on our scale."
Share this study with friends
Copy Link
Messenger